Aspirin-exacerbated respiratory disease: an update. Issue 1 (January 2017)
- Record Type:
- Journal Article
- Title:
- Aspirin-exacerbated respiratory disease: an update. Issue 1 (January 2017)
- Main Title:
- Aspirin-exacerbated respiratory disease: an update
- Authors:
- Le Pham, Duy
Lee, Ji-Ho
Park, Hae-Sim - Abstract:
- Abstract : Purpose of review: The pathophysiology of aspirin-exacerbated respiratory disease (AERD) is not fully understood and diagnostic methods and so far, treatments for AERD have not been standardized. We summarize recent research into the pathological mechanisms of AERD, diagnostic methods, and treatments for AERD patients. Recent findings: In AERD pathophysiology, not only the reduced expression of E prostanoid 2 but also the dysfunction of its pathway could be involved. Moreover, eosinophils of AERD patients could be directly activated by aspirin to produce prostaglandin D2. Platelet activations are well known to be involved in AERD; however, plasma markers do not change during aspirin challenge tests. Additionally, novel genetic polymorphisms, such as P2RY12 and dipeptidyl peptidase 10 gene, and epigenetic predispositions of AERD were found. In AERD diagnosis, bronchial and nasal aspirin challenges have been applied in addition to oral challenge. Serum periostin has been suggested as a potential biomarker for AERD. Apart from standard pharmacological treatment and aspirin desensitization, biologics, including omalizumab and mepolizumab, as well as CRTH2 antagonists have been suggested as promising therapies for AERD treatment. Summary: AERD is usually associated with severe asthma phenotypes. AERD pathophysiology mainly involves the dysregulation of eicosanoid metabolisms, activations of effector cells, which could be influenced by genetic/epigenetic factors.Abstract : Purpose of review: The pathophysiology of aspirin-exacerbated respiratory disease (AERD) is not fully understood and diagnostic methods and so far, treatments for AERD have not been standardized. We summarize recent research into the pathological mechanisms of AERD, diagnostic methods, and treatments for AERD patients. Recent findings: In AERD pathophysiology, not only the reduced expression of E prostanoid 2 but also the dysfunction of its pathway could be involved. Moreover, eosinophils of AERD patients could be directly activated by aspirin to produce prostaglandin D2. Platelet activations are well known to be involved in AERD; however, plasma markers do not change during aspirin challenge tests. Additionally, novel genetic polymorphisms, such as P2RY12 and dipeptidyl peptidase 10 gene, and epigenetic predispositions of AERD were found. In AERD diagnosis, bronchial and nasal aspirin challenges have been applied in addition to oral challenge. Serum periostin has been suggested as a potential biomarker for AERD. Apart from standard pharmacological treatment and aspirin desensitization, biologics, including omalizumab and mepolizumab, as well as CRTH2 antagonists have been suggested as promising therapies for AERD treatment. Summary: AERD is usually associated with severe asthma phenotypes. AERD pathophysiology mainly involves the dysregulation of eicosanoid metabolisms, activations of effector cells, which could be influenced by genetic/epigenetic factors. Understanding the pathophysiology of AERD is key to improve the diagnostic methods and proper management of AERD patients. … (more)
- Is Part Of:
- Current opinion in pulmonary medicine. Volume 23:Issue 1(2017:Jan.)
- Journal:
- Current opinion in pulmonary medicine
- Issue:
- Volume 23:Issue 1(2017:Jan.)
- Issue Display:
- Volume 23, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 23
- Issue:
- 1
- Issue Sort Value:
- 2017-0023-0001-0000
- Page Start:
- 89
- Page End:
- 96
- Publication Date:
- 2017-01
- Subjects:
- aspirin-exacerbated respiratory disease -- asthma -- diagnosis -- pathophysiology -- treatment
Respiratory organs -- Diseases -- Periodicals
616.24 - Journal URLs:
- http://journals.lww.com/co-pulmonarymedicine/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/MCP.0000000000000328 ↗
- Languages:
- English
- ISSNs:
- 1070-5287
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.777200
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4946.xml